MRKR Marker Therapeutics
- 4.6200
- -0.1600-3.35%
Marker Therapeutics News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersENDRA Life Sciences (NASDAQ:NDRA) stock increased by 71.6% to $0.15 during Wednesday's pre-market session. The company's market cap stands at $1.5 million. Concord Medical Services (NYSE:CCM) s
Marker Therapeutics' Promising Cancer Therapy Progress
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M
04:16 PM EDT, 05/15/2024 (MT Newswires) -- Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M
Express News | Marker Therapeutics Inc: Believes That Existing Cash and Cash Equivalents Will Fund Its Operating Expenses Into Q4 of 2025
Express News | Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Express News | Marker Therapeutics Q1 Net Income USD -2.4 Million
Express News | Marker Therapeutics Q1 Basic EPS USD -0.27
Marker Therapeutics | 10-Q: Quarterly report
Marker Therapeutics Initiated at Buy by Ladenburg Thalmann
Marker Therapeutics Initiated at Buy by Ladenburg Thalmann
Express News | Ladenburg Thalmann Initiates Coverage On Marker Therapeutics With Buy Rating, Announces Price Target of $11
Marker Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/30/2024 174.31% Ladenburg Thalmann → $11 Initiates Coverage On → Buy 02/17/2022 -75.06% Roth Capital $3
Marker Therapeutics' MT-601 Shows Promising Results
Marker Therapeutics Advances in Immuno-Oncology
Marker Therapeutics GAAP EPS of -$1.59, Revenue of $3.31M
Express News | Marker Therapeutics Reports 2023 Net Loss Of $(8.2)M Vs. Net Loss Of $(29.9)M Last Year
Press Release: Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response
Marker Therapeutics Ends Stock Sale Deal With LPC
Express News | Marker Therapeutics Receives Approval From United States Adopted Name Council and International Nonproprietary Names Expert Committee for "Neldaleucel" as Nonproprietary Name for MT-601
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Marker Therapeutics, Inc. (Nasdaq: MRKR) today announced a restructuring of its clinical programs and a strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline. In addition, the Company reported a clinical update on the Phase 2 ARTEMIS study investigating MT-401, a multiTAA-specific T cell product, for the treatment of patients with acute myeloid leukemia (AML).
Express News | Marker Therapeutics Says 'MultiTAA-specific T Cell Therapies Demonstrate Clinical Safety and Positive Clinical Data Across Multiple Indications'
Analysis
Price Target
No Data
